# A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)

> **NCT05314010** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Beijing Mabworks Biotech Co., Ltd.** · enrollment: 102 (actual)

## Conditions studied

- Neuromyelitis Optica Spectrum Disorder

## Interventions

- **DRUG:** MIL62
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05314010
- **Lead sponsor:** Beijing Mabworks Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-18
- **Primary completion:** 2025-02-21
- **Final completion:** 2027-03
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2025-09-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05314010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05314010, "A Study of MIL62 in Patients With Neuromyelitis Optica Spectrum Disorder (NMOSD)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05314010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*